{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-216844","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.692392+00:00","generated_at":"2026-06-24T01:23:02.278006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aadi Bioscience Q2 2022: FYARRO sales $3.4M, net loss $18.3M, cash $118.7M","bullets":["FYARRO net product sales $3.4M for Q2 2022, first full quarter after launch.","Net loss $18.3M (vs $1.5M in Q2 2021), includes $3.7M impairment charge.","Cash and equivalents $118.7M; expected to fund operations into 2024.","PRECISION 1 trial (TSC1/TSC2) enrollment ongoing; preliminary data expected 1H23.","Permanent J-code (J9331) for FYARRO effective July 1, 2022 from CMS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-216844","json":"https://secwatch.observer/filing/0001193125-22-216844.json","markdown":"https://secwatch.observer/filing/0001193125-22-216844.md","text":"https://secwatch.observer/filing/0001193125-22-216844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522216844/0001193125-22-216844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522216844/d349452d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:23:02.278006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}